Table 3.

Treatment patterns during the 12-month post-index period and healthcare resource utilization during the 6-month pre-index and 12-month post-index periods in commercially insured acromegalic individuals, by study cohort

	6-month pre-index period			12-month post-index period
	Medical therapy (N = 169)	Surgical therapy (N = 228)	p value	Medical therapy (N = 169)	Surgical therapy (N = 228)	p value
Treatment patterns
Tumor resection surgery	NA	NA	NA	0.0	100.0	NA
Stereotactic radiosurgery radiotherapy	NA	NA	NA	3.0	4.8	0.350
Medical therapy	NA	NA	NA	100.0	31.6	<0.001
Somatostatin analogue treatment
Lanreotide depot	NA	NA	NA	10.7	11.0	0.921
Octreotide	NA	NA	NA	6.5	9.2	0.328
Octreotide LAR	NA	NA	NA	37.9	11.0	<0.001
Growth hormone receptor antagonists
Pegvisomant	NA	NA	NA	16.0	5.3	<0.001
Dopamine agonists
Bromocriptine	NA	NA	NA	11.8	2.6	<0.001
Cabergoline	NA	NA	NA	37.3	5.7	<0.001
Healthcare resource utilization
Hospitalization admissions	11.2	10.1	0.711	13.6	98.3	<0.001
Number of inpatient admissions	0.2 (0.5)	0.1 (0.5)	0.716	0.2 (0.7)	1.2 (0.6)	<0.001
Length of stay	1.1 (5.7)	0.6 (2.4)	0.694	1.1 (6.0)	4.0 (3.5)	<0.001
Hospital outpatient visits	59.8	68.4	0.074	81.1	94.7	<0.001
Number of visits	2.2 (4.1)	2.9 (4.8)	0.014	5.2 (6.9)	10.2 (10.4)	<0.001
Emergency room visits	12.4	18.9	0.085	20.7	29.8	0.041
Number of visits	0.1 (0.4)	0.5 (2.8)	0.063	0.4 (1.3)	0.8 (3.1)	0.015
Physician office visits	87.6	93.0	0.067	99.4	98.7	0.475
Number of visits	6.3 (6.7)	8.8 (8.7)	<0.001	15.0 (13.3)	21.2 (14.3)	<0.001
Specialist office visits	33.1	34.2	0.823	54.4	68.0	0.006
Endocrinologist	26.6	23.3	0.440	51.5	61.4	0.048
Neurosurgeon	7.7	15.8	0.015	7.1	20.2	<0.001
Oncologist	1.2	1.8	0.645	4.1	6.6	0.294

Data are presented as % or mean (standard deviation) unless otherwise indicated

LAR long-acting release, NA not available